ALK and non-small cell lung carcinoma: In a single-arm, open-label, phase I–II study, NSCLC patients harboring ALK rearrangements (phase I, n = 24; phase II, n = 46) were given crizotinib (phase I, 20–300 mg/bid; phase II, 300 mg/bid).